Amgen (AMGN)
Develops and manufactures medicines and biosimilars across general medicine, rare disease, inflammation, and oncology.
$401.86
vs last close+8.70 (+2.21%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6,903 | 8,196 | 7,447 | 8,388 | 8,503 | 9,086 | 8,149 | 9,167 | 9,557 | 9,896 | 8,618 | 10,054 |
| Cost of revenue | 1,806 | 3,112 | 3,200 | 3,236 | 3,310 | 3,112 | 2,968 | 3,011 | 3,082 | 1,790 | 2,744 | 2,811 |
| Gross profit | 5,097 | 5,084 | 4,247 | 5,152 | 5,193 | 5,974 | 5,181 | 6,156 | 6,475 | 8,106 | 5,874 | 7,243 |
| 3,076 | 3,813 | 3,256 | 3,243 | 3,146 | 3,663 | 4,003 | 3,512 | 3,949 | 4,164 | 3,208 | 3,729 | |
| Research & development | 1,079 | 1,534 | 1,343 | 1,447 | 1,450 | 1,724 | 1,486 | 1,744 | 1,900 | 2,151 | 1,719 | 1,868 |
| 1,353 | 2,274 | 1,808 | 1,785 | 1,625 | 1,878 | 1,687 | 1,691 | 1,720 | 1,937 | 1,602 | 1,745 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 987 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 891 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other expenses | 644 | 5 | 105 | 11 | 71 | 61 | 830 | 77 | 329 | 76 | −113 | 116 |
| Operating income | 2,021 | 1,271 | 991 | 1,909 | 2,047 | 2,311 | 1,178 | 2,644 | 2,526 | 3,942 | 2,666 | 3,514 |
| −74 | −419 | −1,059 | −1,115 | 1,054 | −1,529 | 795 | −1,076 | 1,395 | −2,428 | −582 | −746 | |
| Interest expense | 759 | 821 | 824 | 808 | 776 | 747 | 723 | 708 | 685 | 653 | 657 | 673 |
| Other non-operating income | −685 | −402 | 235 | 307 | −1,830 | 782 | −1,518 | 368 | −2,080 | 1,775 | −75 | 73 |
| Income before tax | 1,947 | 852 | −68 | 794 | 3,101 | 782 | 1,973 | 1,568 | 3,921 | 1,514 | 2,084 | 2,768 |
| Income tax expense | 217 | 85 | 45 | 48 | 271 | 155 | 243 | 136 | 705 | 181 | 265 | 393 |
| Net income from continuing operations | 1,730 | 767 | −113 | 746 | 2,830 | 627 | 1,730 | 1,432 | 3,216 | 1,333 | 1,819 | 2,375 |
| Net income | 1,730 | 767 | −113 | 746 | 2,830 | 627 | 1,730 | 1,432 | 3,216 | 1,333 | 1,819 | 2,375 |
| EPS, basic | $3.23 | $1.43 | −$0.21 | $1.39 | $5.27 | $1.17 | $3.22 | $2.66 | $5.98 | $2.47 | $3.37 | $4.40 |
| EPS, diluted | $3.22 | $1.42 | −$0.21 | $1.38 | $5.22 | $1.16 | $3.20 | $2.65 | $5.93 | $2.45 | $3.34 | $4.37 |
| Weighted average shares, basic | 535 | 535 | 536 | 537 | 537 | 541 | 538 | 538 | 538 | 539 | 540 | 540 |
| Weighted average shares, diluted | 538 | 540 | 536 | 541 | 542 | 542 | 541 | 541 | 542 | 543 | 544 | 544 |
| EBITDA | 3,601 | 3,053 | 2,155 | 3,002 | 5,273 | 2,926 | 4,083 | 3,617 | 5,913 | 3,299 | 3,857 | 3,441 |
| Depreciation & amortization | 895 | 1,380 | 1,399 | 1,400 | 1,396 | 1,397 | 1,387 | 1,341 | 1,307 | 1,132 | 1,116 | 0 |
| EBIT | 2,706 | 1,673 | 756 | 1,602 | 3,877 | 1,529 | 2,696 | 2,276 | 4,606 | 2,167 | 2,741 | 3,441 |